Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
Add more filters










Publication year range
4.
NPJ Parkinsons Dis ; 7(1): 73, 2021 Aug 16.
Article in English | MEDLINE | ID: mdl-34400650

ABSTRACT

The lack of knowledge about the onset and progression of Parkinson's disease (PD) hampers its early diagnosis and treatment. Metabolomics might shed light on the PD imprint seeking a broader view of the biochemical remodeling induced by this disease in an early and pre-symptomatic stage and unveiling potential biomarkers. To achieve this goal, we took advantage of the great potential of the European Prospective Study on Nutrition and Cancer (EPIC) cohort to apply metabolomics searching for early diagnostic PD markers. This cohort consisted of healthy volunteers that were followed for around 15 years until June 2011 to ascertain incident PD. For this untargeted metabolomics-based study, baseline preclinical plasma samples of 39 randomly selected individuals that developed PD (Pre-PD group) and the corresponding control group were analyzed using a multiplatform approach. Data were statistically analyzed and exposed alterations in 33 metabolites levels, including significantly lower levels of free fatty acids (FFAs) in the preclinical samples from PD subjects. These results were then validated by adopting a targeted HPLC-QqQ-MS approach. After integrating all the metabolites affected, our finding revealed alterations in FFAs metabolism, mitochondrial dysfunction, oxidative stress, and gut-brain axis dysregulation long before the development of PD hallmarks. Although the biological purpose of these events is still unknown, the remodeled metabolic pathways highlighted in this work might be considered worthy prognostic biomarkers of early prodromal PD. The findings revealed by this work are of inestimable value since this is the first study conducted with samples collected many years before the disease development.

6.
J Neurooncol ; 148(3): 545-554, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32524392

ABSTRACT

INTRODUCTION: To assess the management of immunocompetent patients with primary central nervous system lymphomas (PCNSL) in Spain. METHODS: Retrospective analysis of 327 immunocompetent patients with histologically confirmed PCNSL diagnosed between 2005 and 2014 in 27 Spanish hospitals. RESULTS: Median age was 64 years (range: 19-84; 33% ≥ 70 years), 54% were men, and 59% had a performance status (PS) ≥ 2 at diagnosis. Median delay to diagnosis was 47 days (IQR 24-81). Diagnostic delay > 47 days was associated with PS ≥ 2 (OR 1.99; 95% CI 1.13-3.50; p = 0.016) and treatment with corticosteroids (OR 2.47; 95% CI 1.14-5.40; p = 0.023), and it did not improve over the years. Patients treated with corticosteroids (62%) had a higher risk of additional biopsies (11.7% vs 4.0%, p = 0.04) but corticosteroids withdrawal before surgery did not reduce this risk and increased the diagnostic delay (64 vs 40 days, p = 0.04). Median overall survival (OS) was 8.9 months [95% CI 5.9-11.7] for the whole series, including 52 (16%) patients that were not treated, and 14.1 months (95%CI 7.7-20.5) for the 240 (73.4%) patients that received high-dose methotrexate (HD-MTX)-based chemotherapy. Median OS was shorter in patients ≥ 70 years (4.1 vs. 13.4 months; p < 0.0001). Multivariate analysis identified age ≥ 65 years, PS ≥ 2, no treatment, and cognitive/psychiatric symptoms at diagnosis as independent predictors of short survival. CONCLUSIONS: Corticosteroids withdrawal before surgery does not decrease the risk of a negative biopsy but delays diagnosis. In this community-based study, only 73.4% of patients could receive HD-MTX-based chemotherapy and OS remains poor, particularly in elderly patients ≥ 70 years.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Central Nervous System Neoplasms/mortality , Chemoradiotherapy/mortality , Cranial Irradiation/mortality , Delayed Diagnosis/statistics & numerical data , Immunocompetence , Lymphoma, Non-Hodgkin/mortality , Adult , Aged , Aged, 80 and over , Carmustine/administration & dosage , Central Nervous System Neoplasms/diagnosis , Central Nervous System Neoplasms/immunology , Central Nervous System Neoplasms/therapy , Cytarabine/administration & dosage , Female , Follow-Up Studies , Humans , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/immunology , Lymphoma, Non-Hodgkin/therapy , Male , Methotrexate/administration & dosage , Middle Aged , Prognosis , Retrospective Studies , Survival Rate , Young Adult
8.
J Neurol ; 266(10): 2396-2405, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31190169

ABSTRACT

OBJECTIVE: To describe the clinical, biochemical, and neuropathological findings of an autosomal dominant globular glial tauopathy caused by the P301T mutation at the MAPT gene. METHODS: Five patients from two unrelated pedigrees underwent clinical evaluation. Genetic analysis, brain pathological examination, and biochemical analysis of tau were performed. RESULTS: The patients studied were 3 men and 2 women with a mean age at onset of 52.2 years and mean disease duration of 5.2 years. Three patients presented a corticobasal syndrome, one patient an asymmetric pyramidal syndrome compatible with primary lateral sclerosis, and one patient a frontotemporal dementia. In both pedigrees (4 patients) Sanger sequencing showed the p.P301T mutation in exon 10 of the MAPT gene. Neuropathological findings consisted of atrophy of frontal and temporal lobes with marked spongiosis and astrogliosis, and abundant phosphorylated tau protein deposits in the frontal and temporal cortex, limbic area, basal ganglia, and brain stem. The most striking finding was the presence of oligodendroglial 4R phospho-tau globular positive inclusions in the white matter and cortex. Globose-type neurofibrillary neuronal tangles, and in particular astrocytic globular inclusions and coarse tufts, were present in the grey matter. Biochemical analysis of sarkosyl-insoluble fractions revealed two tau bands of 64 and 68 kDa and case-dependent bands of lower molecular weight. CONCLUSION: This is the first pathological and biochemical study of the MAPT p.P301T mutation showing variable clinical manifestation and neuropathological phenotype of globular glial tauopathy not only among different families but also within families.


Subject(s)
Gray Matter , Neuroglia , Tauopathies , White Matter , tau Proteins/metabolism , Aged , Female , Gray Matter/metabolism , Gray Matter/pathology , Humans , Male , Middle Aged , Neuroglia/metabolism , Neuroglia/pathology , Pedigree , Spain , Tauopathies/genetics , Tauopathies/metabolism , Tauopathies/pathology , Tauopathies/physiopathology , White Matter/metabolism , White Matter/pathology , tau Proteins/genetics
9.
Rev Neurol ; 68(6): 266-267, 2019 Mar 16.
Article in Spanish | MEDLINE | ID: mdl-30855712

ABSTRACT

TITLE: Linfoma primario del sistema nervioso central de localizacion inhabitual: un reto diagnostico.


Subject(s)
Brain Neoplasms/diagnosis , Lymphoma/diagnosis , Aged , Humans , Male
11.
Rev Neurol ; 50 Suppl 2: S7-13, 2010 Feb 08.
Article in Spanish | MEDLINE | ID: mdl-20205146

ABSTRACT

INTRODUCTION: The neuro-anatomical and neurochemical substrates underlying most of the non-motor symptoms (NMS) of Parkinson's disease (PD) are not understood in depth. AIM: To review the current knowledge on the pathophysiology of the different NMS of PD based on recent studies. DEVELOPMENT: In most of the NMS the pathophysiological foundation is complex. In addition to the dopaminergic dysfunction, the degeneration of non-dopaminergic (i.e. noradrenergic, serotoninergic and cholinergic) cellular systems is thought to underlie the development of most of the NMS and can be applied in dementia, depression, sleep disorders and vegetative disorders. Dementia, moreover, is essentially caused by different alterations that take place with the cerebral cortex. Dysfunction of the ventral striatum and of the mesolimbic projections exerts a crucial influence in impulsive-compulsive spectrum disorder. Loss of the sense of smell appears to be due to the neuronal degeneration of the olfactory bulb and the pain has an extremely varied pathogenetic basis and may be musculoskeletal, dystonic, radicular or central. CONCLUSIONS: Despite the fact that a huge amount of progress has been made in research on the pathophysiology of the NMS of PD, further clinicopathological and pathobiochemical comparative studies are needed to explain the pathophysiological bases of PD and to provide a broader foundation for future therapeutic strategies to treat NMS.


Subject(s)
Parkinson Disease/physiopathology , Dementia/etiology , Dementia/physiopathology , Humans , Mental Disorders/etiology , Mental Disorders/physiopathology , Olfaction Disorders/etiology , Olfaction Disorders/physiopathology , Pain/etiology , Pain/physiopathology , Parkinson Disease/complications , Sleep Wake Disorders/etiology , Sleep Wake Disorders/physiopathology
12.
Rev Neurol ; 48 Suppl 1: S1-6, 2009 Jan 23.
Article in Spanish | MEDLINE | ID: mdl-19222008

ABSTRACT

INTRODUCTION: Myoclonus refers to the brief, sudden, involuntary movements like jerks or twitches which produce a sudden muscular contraction. AIMS: To review the clinical and neurophysiological features of myoclonus, or myoclonic spasms, and to carry out an updated examination of their causation and treatment. DEVELOPMENT: Myoclonic spasms can be classified on the basis of different criteria. According to the underlying physiological mechanism, myoclonic spasms can be classified as cortical, subcortical, spinal or peripheral. Myoclonic spasms appear in a wide range of neurological diseases. So-called symptomatic myoclonus is the type that occurs secondary to an identifiable disorder; it is usually accompanied by other neurological signs and is the most frequent kind. Epileptic myoclonus is that which forms part of an epileptic syndrome with a genetic or idiopathic cause, or that is due to static encephalopathy. Essential myoclonus is the least frequent type and includes palatal myoclonus and dystonia-myoclonus syndrome. The main therapeutic objective consists in treating the underlying cause of the myoclonus if possible and in using symptomatic treatment when this is not the case. Antiepileptic drugs that enhance the effect of gamma-aminobutyric acid are still the most effective medication. Among the non-antiepileptic drugs, piracetam and 5-hydroxytryptophan stand out above the rest. Botulinum toxin has proved to be effective in palatal myoclonus. In dystonia-myoclonus syndrome, research has been conducted on the effectiveness of deep brain stimulation on the internal globus pallidus. In the most severe forms of myoclonus, monotherapy is not usually effective. CONCLUSIONS: Progress has been made in furthering our knowledge of the neurophysiology of myoclonus, although no very effective forms of treatment have been reported for this motor disorder, which can be extremely disabling.


Subject(s)
Myoclonus , 5-Hydroxytryptophan/therapeutic use , Anticonvulsants/therapeutic use , Antidepressive Agents, Second-Generation/therapeutic use , Diagnosis, Differential , Humans , Myoclonus/drug therapy , Myoclonus/etiology , Myoclonus/physiopathology , Nervous System Diseases/complications , Nervous System Diseases/physiopathology , Neuroprotective Agents/therapeutic use , Piracetam/therapeutic use , gamma-Aminobutyric Acid/metabolism
14.
An Sist Sanit Navar ; 31 Suppl 1: 127-40, 2008.
Article in Spanish | MEDLINE | ID: mdl-18528449

ABSTRACT

Acute or sub-acute movement disorders represent a small percentage of neurological emergencies but it is necessary to be aware of their existence because a failure in their diagnosis or treatment can result in significant morbidity and mortality. Clinical presentation of acute movement disorders can be diverse. In some cases acinesia or rigidity predominates, while others are characterized by dystonia, chorea o balism. The type of movement disorder suggest a specific aetiology. Drugs represent the most frequent etiologic factor and are the cause of neuroleptic malignant syndrome and serotoninergic syndrome. Emergencies secondary to Parkinson's disease are reviewed, including parkinsonism-hyperpirexia syndrome, acute psychosis and the emergencies derived from deep brain stimulators. Different aetiologies of acute dystonia and chorea are also covered and, finally, acute movement disorders due to stroke are reviewed.


Subject(s)
Emergency Treatment , Movement Disorders , Acute Disease , Algorithms , Dystonia/diagnosis , Dystonia/therapy , Humans , Movement Disorders/diagnosis , Movement Disorders/therapy , Parkinson Disease/diagnosis , Parkinson Disease/therapy , Serotonin Syndrome/diagnosis , Serotonin Syndrome/therapy
15.
Neurologia ; 23(4): 256-8, 2008 May.
Article in Spanish | MEDLINE | ID: mdl-18516747

ABSTRACT

INTRODUCTION: Spontaneous non-aneurysmal subarachnoid hemorrhages generally have a good short and long term outcome, especially those with a perimesencephalic location. Vasospasm is an uncommon complication of this type of subarachnoid hemorrhage, and ischemic cerebral lesions related to vasospasm are even less frequent. CASE REPORT: A 46 year-old man was admitted with a perimesencephalic subarachnoid hemorrhage. Angiographic study performed on admission was normal. Two weeks later he developed dysarthria and right faciobrachial paresis. Transcranial doppler showed a diffuse and moderate increase of medium velocity flow at basilar artery level suggestive of moderate vasospasm. An angioresonance confirmed this finding and a paramedian pontine infarction was found on resonance images. The patient was treated with nimodipine and he was discharged from hospital with only mild residual deficit. CONCLUSION: Cerebral infarction related to vasospasm as complication of subarachnoid perimesencephalic hemorrhage is exceptional. The factors that could have been involved in the development of this complication are discussed.


Subject(s)
Brain Stem/blood supply , Stroke/etiology , Subarachnoid Hemorrhage/complications , Subarachnoid Hemorrhage/diagnosis , Vasospasm, Intracranial/etiology , Humans , Male , Mesencephalon , Middle Aged
17.
Neurologia ; 22(7): 475-9, 2007 Sep.
Article in Spanish | MEDLINE | ID: mdl-17853968

ABSTRACT

INTRODUCTION: The appearance of movement disorders in vascular disease of the brainstem has hardly been described in the literature. Its frequency is probably underestimated due to their briefness and that they are often misinterpreted as epileptic seizures. Their pathophysiological mechanism is uncertain. Several mechanisms, such as the existence of a seizure-generating brainstem center, capable of generating epileptic activity or the interruption of the corticospinal tracts due to ischemia, have been proposed. CLINICAL CASES: We present three patients with disease of the basilar artery and extensive brainstem infarction who have the presentation of sudden, involuntary movements in limbs in the initial phase, in paroxysms of short duration and of varied semiology in common. We described this in all of them. An electroencephalographic functional study during these episodes was done in one of the cases. CONCLUSIONS: Preservation of conscious level, its variability of presentation, the null response to antiepileptic drugs and normality of the electroencephalogram in one of them leads us to ratify the hypothesis of failure of the cortical inhibitory projections as subcortical centers in trunk or spinal cord as pathophysiological origin of these involuntary movements. We stress the importance of recognizing these clinical manifestations of appearance in the initial phases of the disease, that permit a rapid diagnosis with the help of the transcranial Doppler to establish an early and aggressive treatment of this disease having known seriousness and bad prognosis. Further prospective studies would be interesting to know what the real incidence of these movements is, and functional ones to clarify the pathophysiological nature of this phenomenon.


Subject(s)
Brain Infarction , Brain Stem , Cerebrovascular Disorders , Movement Disorders , Adult , Basilar Artery/pathology , Brain Infarction/complications , Brain Infarction/pathology , Brain Stem/blood supply , Brain Stem/pathology , Cerebrovascular Disorders/complications , Cerebrovascular Disorders/pathology , Fatal Outcome , Humans , Male , Middle Aged , Movement Disorders/etiology , Movement Disorders/pathology
18.
Neurología (Barc., Ed. impr.) ; 22(7): 475-479, sept. 2007. ilus
Article in Es | IBECS | ID: ibc-62668

ABSTRACT

Introducción. La aparición de trastornos del movimiento en patología vascular del tronco del encéfalo ha sido escasamente descrita en la literatura existente y es probable que su frecuencia esté siendo subestimada por su breve duración y la confusión con movimientos clónicos de origen epiléptico. Su fisiopatología se mantiene incierta y se han propuesto varios mecanismos como la existencia de un centro infratentorial capaz de generar actividad epiléptica o la interrupción por isquemia de los tractos corticoespinales. Casos clínicos. Presentamos tres pacientes con enfermedad de la arteria basilar e infarto extenso del tronco del encéfalo que tienen en común la presentación en la fase inicial de movimientos bruscos involuntarios en extremidades, en paroxismos de duración breve y de semiología variada, que describimos en todos ellos. En uno de los casos se realizó un estudio funcional electroencefalográfico durante estos episodios. Conclusiones. La preservación de la conciencia, su variabilidad de presentación, la nula respuesta a fármacos antiepilépticos y la normalidad del electroencefalograma en uno de ellos nos inclinan a ratificar la hipótesis del fallo de las proyecciones inhibitorias corticales sobre centros subcorticales en tronco o médula espinal como origen fisiopatológico de estos movimientos involuntarios. Queremos destacar la importancia de reconocer estas manifestaciones clínicas de aparición en fases iniciales de la enfermedad que permitirán un rápido diagnóstico con ayuda del doppler transcraneal para instaurar un tratamiento precoz y agresivo de esta patología de conocida gravedad y mal pronóstico. Serían interesantes estudios prospectivos para conocer la incidencia real de estos fenómenos, así como estudios funcionales que nos ayuden a aclarar su naturaleza (AU)


Introduction. The appearance of movement disorders in vascular disease of the brainstem has hardly been described in the literature. Its frequency is probably underestimated due to their briefness and that they are often misinterpreted as epileptic seizures. Their pathophysiological mechanism is uncertain. Several mechanisms, such as the existence of a seizure-generating brainstem center, capable of generating epileptic activity or the interruption of the corticospinal tracts due to ischemia, have been proposed. Clinical cases. We present three patients with disease of the basilar artery and extensive brainstem infarction who have the presentation of sudden, involuntary movements in limbs in the initial phase, in paroxysms of short duration and of varied semiology in common. We described this in all of them. An electroencephalographic functional study during these episodes was done in one of the cases. Conclusions. Preservation of conscious level, its variability of presentation, the null response to antiepileptic drugs and normality of the electroencephalogram in one of them leads us to ratify the hypothesis of failure of the cortical inhibitory projections as subcortical centers in trunk or spinal cord as pathophysiological origin of these involuntary movements. We stress the importance of recognizing these clinical manifestations of appearance in the initial phases of the disease, that permit a rapid diagnosis with the help of the transcranial Doppler to establish an early and aggressive treatment of this disease having known seriousness and bad prognosis. Further prospective studies would be interesting to know what the real incidence of these movements is, and functional ones to clarify the pathophysiological nature of this phenomenon (AU)


Subject(s)
Humans , Male , Adult , Middle Aged , Brain Ischemia/physiopathology , Movement Disorders/etiology , Brain Ischemia/drug therapy , Brain Ischemia/diagnosis , Brain Stem/injuries , Basilar Artery/injuries , Anticonvulsants/therapeutic use , Signs and Symptoms
20.
An Sist Sanit Navar ; 30 Suppl 1: 113-20, 2007.
Article in Spanish | MEDLINE | ID: mdl-17486152

ABSTRACT

Hypersomnia or excessive daytime sleepiness is common in neurological practice and may have different etiologies. Hypersomnia may be defined as sleepiness at an inappropriate time or in an inappropriate situation. It is important to consider that hypersomnia is at times referred to as tiredness or fatigue. A detailed clinical history is essential to reach an accurate diagnosis. A correct diagnosis is necessary to initiate the appropriate treatment considering the negative social and occupational consequences of hypersomnia. Excessive daytime sleepiness syndromes include primary sleep disorders like narcolepsy and hypersomnia secondary to several neurological and psychiatric disorders and also as an adverse effect of numerous drugs.


Subject(s)
Disorders of Excessive Somnolence , Disorders of Excessive Somnolence/classification , Disorders of Excessive Somnolence/diagnosis , Disorders of Excessive Somnolence/therapy , Humans , Narcolepsy/classification , Narcolepsy/diagnosis , Narcolepsy/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...